Regular inhaled corticosteroids in adult-onset asthma and the risk for future cancer: a population-based cohort study with proper person-time analysis

被引:12
作者
Kok, Victor C. [1 ]
Horng, Jorng-Tzong [1 ,2 ]
Huang, Hsu-Kai [2 ]
Chao, Tsung-Ming [3 ]
Hong, Ya-Fang [4 ]
机构
[1] Asia Univ Taiwan, Dept Biomed Informat, Taichung, Taiwan
[2] Natl Cent Univ, Dept Comp Sci & Informat Engn, Jhongli, Taiwan
[3] Chien Hsin Univ, Dept Appl Geomat, Stat Unit, Jhongli, Taiwan
[4] Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan
来源
THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2015年 / 11卷
关键词
immortal time bias; NHIRD; population-based study; retrospective cohort study; risk of cancer; OBSTRUCTIVE PULMONARY-DISEASE; IMMORTAL TIME; LUNG-CANCER; CARDIOVASCULAR MORTALITY; BUDESONIDE; BIAS; COPD; TAIWAN; WOMEN; TRIAL;
D O I
10.2147/TCRM.S80793
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Recent studies have shown that inhaled corticosteroids (ICS) can exert anti-inflammatory effects for chronic airway diseases, and several observational studies suggest that they play a role as cancer chemopreventive agents, particularly against lung cancer. We aimed to examine whether regular ICS use was associated with a reduced risk for future malignancy in patients with newly diagnosed adult-onset asthma. Methods: We used a population-based cohort study between 2001 and 2008 with appropriate person-time analysis. Participants were followed up until the first incident of cancer, death, or to the end of 2008. The Cox model was used to derive an adjusted hazard ratio (aHR) for cancer development. Kaplan-Meier cancer-free survival curves of two groups were compared. Results: The exposed group of 2,117 regular ICS users and the nonexposed group of 17,732 non-ICS users were assembled. After 7,365 (mean, 3.5 years; standard deviation 2.1) and 73,789 (mean, 4.1 years; standard deviation 2.4) person-years of follow-up for the ICS users and the comparator group of non-ICS users, respectively, the aHR for overall cancer was nonsignificantly elevated at 1.33 with 95% confidence interval (CI), 1.00-1.76, P=0.0501. The Kaplan-Meier curves for overall cancer-free proportions of both groups were not significant (log-rank, P=0.065). Synergistic interaction of concurrent presence of regular ICS use was conducted using "ICS-negative and chronic obstructive pulmonary disease (COPD)-negative" as the reference. The aHR for the group of "ICS-positive, COPD-negative" did not reach statistically significant levels with aHR at 1.38 (95% CI, 0.53-3.56). There was a statistically significant synergistic interaction of concurrent presence of regular ICS use and COPD with aHR at 3.78 (95% CI, 2.10-6.81). Conclusion: The protective effect of regular ICS use in the studied East Asian patients with adult-onset asthma was not detectable, contrary to reports of previous studies that ICS might prevent the occurrence of future cancer.
引用
收藏
页码:489 / 499
页数:11
相关论文
共 29 条
  • [1] Three phenotypes of adult-onset asthma
    Amelink, M.
    de Nijs, S. B.
    de Groot, J. C.
    van Tilburg, P. M. B.
    van Spiegel, P. I.
    Krouwels, F. H.
    Lutter, R.
    Zwinderman, A. H.
    Weersink, E. J. M.
    ten Brinke, A.
    Sterk, P. J.
    Bel, E. H.
    [J]. ALLERGY, 2013, 68 (05) : 674 - 680
  • [2] Immortal Person Time Bias in Pharmacoepidemiological Studies of Antihypertensive Drugs
    Assimes, Themistocles L.
    Suissa, Samy
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (06) : 902 - 903
  • [3] Prospective study of inhaled corticosteroid use, cardiovascular mortality, and all-cause mortality in asthmatic women
    Camargo, Cartos A., Jr.
    Barr, R. Graham
    Chen, Rong
    Speizer, Frank E.
    [J]. CHEST, 2008, 134 (03) : 546 - 551
  • [4] Adult-onset asthma: is it really different?
    de Nijs, Selma B.
    Venekamp, Lisette N.
    Bel, Elisabeth H.
    [J]. EUROPEAN RESPIRATORY REVIEW, 2013, 22 (127) : 44 - 52
  • [5] Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan
    Gau, Churn-Shiouh
    Chang, I-Shou
    Lin, Fe-Lin
    Yu, Hui-Tzu
    Huang, Yu-Wen
    Chi, Cheng-Liang
    Chien, Su-Yu
    Lin, Keh-Ming
    Liu, Ming-Ying
    Wang, Hui-Po
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (01) : 86 - 95
  • [6] CONFIDENCE-INTERVAL ESTIMATION OF INTERACTION
    HOSMER, DW
    LEMESHOW, S
    [J]. EPIDEMIOLOGY, 1992, 3 (05) : 452 - 456
  • [7] EFFECT OF LONG-TERM TREATMENT WITH AN INHALED CORTICOSTEROID (BUDESONIDE) ON AIRWAY HYPERRESPONSIVENESS AND CLINICAL ASTHMA IN NONSTEROID-DEPENDENT ASTHMATICS
    JUNIPER, EF
    KLINE, PA
    VANZIELEGHEM, MA
    RAMSDALE, EH
    OBYRNE, PM
    HARGREAVE, FE
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 142 (04): : 832 - 836
  • [8] Comparison of Inhaled Corticosteroids: An Update
    Kelly, H. William
    [J]. ANNALS OF PHARMACOTHERAPY, 2009, 43 (03) : 519 - 527
  • [9] Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking
    Kiri, Victor A.
    Fabbri, Leonardo M.
    Davis, Kourtney J.
    Soriano, Joan B.
    [J]. RESPIRATORY MEDICINE, 2009, 103 (01) : 85 - 90
  • [10] Population-based cohort study on the risk of malignancy in East Asian children with Juvenile idiopathic arthritis
    Kok, Victor C.
    Horng, Jorng-Tzong
    Huang, Jing-Long
    Yeh, Kuo-Wei
    Gau, Jia-Jing
    Chang, Cheng-Wei
    Zhuang, Lai-Zhen
    [J]. BMC CANCER, 2014, 14